Agenus
biotechnology company
AGEN Nasdaq
ISIN US00847G8042 SEC CIK 1098972
Follow Agenus
Weekly email: filings, results
Revenue, last quarter
$31.5M
+4.1% vs same quarter last year
Net income
$2.7M
−95.7% vs same quarter last year
EPS, diluted
$0.02
−99% vs same quarter last year
Operating cash flow
−$20.1M
−36.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $114.2M | −$3.1M |
| FY24 | $103.5M | −$232.3M |
| FY23 | $156.3M | −$257.4M |
| FY22 | $98M | −$230.7M |
| FY21 | $295.7M | −$28.7M |
| FY20 | $88.2M | −$182.9M |
| FY19 | $150M | −$111.6M |
| FY18 | $36.8M | −$162M |
| FY17 | $42.9M | −$120.7M |
| FY16 | $22.6M | −$127M |
| FY15 | $24.8M | −$87.9M |
| FY14 | $7M | −$42.5M |
| FY13 | $3M | −$30.1M |
| FY12 | $16M | −$11.3M |
| FY11 | $2.8M | −$23.3M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 99.1% | −17.7% | −2.7% |
| FY24 | 99.5% | −116.4% | −224.5% |
| FY23 | 98% | −102.1% | −164.7% |
| FY22 | 89.2% | −183% | −235.3% |
| FY21 | 98.8% | 8.7% | −9.7% |
| FY20 | 97.3% | −133% | −207.4% |
| FY19 | - | −46.7% | −74.3% |
| FY18 | - | −336.6% | −440.5% |
| FY17 | - | −242.1% | −281.5% |
| FY16 | - | −476.1% | −562.6% |
| FY15 | - | −325.2% | −354.1% |
| FY14 | 100% | −620.9% | −608.9% |
| FY13 | 82.4% | −820.3% | −987.5% |
| FY12 | 95.8% | −42.2% | −71% |
| FY11 | 100% | −692.6% | −844.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$77.2M |
| FY24 | −$158.9M |
| FY23 | −$234.2M |
| FY22 | −$228.4M |
| FY21 | −$23.7M |
| FY20 | −$142.6M |
| FY19 | −$23.3M |
| FY18 | −$134.7M |
| FY17 | −$97.3M |
| FY16 | −$92.5M |
| FY15 | −$50.8M |
| FY14 | −$41.1M |
| FY13 | −$20.3M |
| FY12 | $909.2K |
| FY11 | −$16.3M |
- Agenus
- Healthcare median
Show the numbers
| Year | Agenus | Healthcare median |
|---|---|---|
| FY25 | −2.7% | −30.6% |
| FY24 | −224.5% | −47% |
| FY23 | −164.7% | −58% |
| FY22 | −235.3% | −80.4% |
| FY21 | −9.7% | −71.8% |
| FY20 | −207.4% | −62.2% |
| FY19 | −74.3% | −46.2% |
| FY18 | −440.5% | −49.6% |
| FY17 | −281.5% | −45.9% |
| FY16 | −562.6% | −36% |
| FY15 | −354.1% | −37.8% |
| FY14 | −608.9% | −35.5% |
| FY13 | −987.5% | −37.1% |
| FY12 | −71% | −29.1% |
| FY11 | −844.6% | −27.9% |